We are creating a new category of transformative medicines based on messenger RNA, or mRNA, to improve the lives of patients. From the beginning, we designed our strategy and operations to realize the full potential value and impact of mRNA over a long time horizon across a broad array of human diseases.
December 7, 2018
Morgan Stanley, Goldman Sachs & Co. LLC, J.P. Morgan, BofA Merrill Lynch, Barclays, Piper Jaffray, Bryan, Garnier & Co., Oddo BHF, Oppenheimer & Co., Needham & Company, Chardan
To view the prospectus for Moderna, Inc. IPO, or any offering listed on ClickIPO,
download the ClickIPO app...
or a prospectus can be requested from G. Price at
ClickIPO Securities, LLC P. O. Box 21154, Mesa, AZ 85277